Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.46 |
| ▸ | ABAT | P80404 | 1/20 | 0.46 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.43 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.37 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4956384 | 0.76 | CYP2A6 (0.69) | CYP2A6ALDH1A1TYRCYP2A13HSD17B10 | |
| SCHEMBL1593230 | 0.76 | — | — | |
| SCHEMBL31171 | 0.76 | CYP2A6 (0.69) | CYP2A6ALDH1A1TYRCYP2A13HSD17B10 | |
| Hydrochloric Acid SCHEMBL28807787 | 0.73 | CYP2A6 (0.65) | CYP2A6ALDH1A1TYRCYP2A13HSD17B10 | |
| Water SCHEMBL29197442 | 0.73 | CYP2A6 (0.65) | CYP2A6ALDH1A1TYRCYP2A13HSD17B10 | |
| SCHEMBL339657 | 0.72 | ALDH1A1 (0.48) | CYP2A6ALDH1A1CYP2A13KDM4ETSHR | |
| Formaldehyde SCHEMBL20477527 | 0.70 | CYP2A6 (0.61) | CYP2A6ALDH1A1TYRCYP2A13HSD17B10 | |
| SCHEMBL8469408 | 0.69 | CYP2A6 (1.00) | CYP2A6ALDH1A1TYRCYP2A13HSD17B10 | |
| P-Xylene SCHEMBL10939332 | 0.69 | CYP2A6 (1.00) | CYP2A6ALDH1A1TYRCYP2A13HSD17B10 | |
| SCHEMBL29171 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117088909-A | Method for producing aryltrimethylstannane compound | 上海致同建设工程科技有限公司 | 2023-11-21 | — | — | CN | claimed |
| US-12534429-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| CN-117088909-A | Method for producing aryltrimethylstannane compound | 上海致同建设工程科技有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20230095637-A1 | Heterodimers of Glutamic Acid | CITIZENS BANK, N.A. | 2023-03-30 | — | — | US | disclosed |
| EP-4023624-A1 | HETERODIMERS OF GLUTAMIC ACID | Molecular Insight Pharmaceuticals, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-3699162-B1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARM INC (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20210246103-A1 | HETERODIMERS OF GLUTAMIC ACID | CITIZENS BANK, N.A. | 2021-08-12 | — | — | US | disclosed |
| US-20210070695-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20210070696-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2021-03-11 | — | — | US | disclosed |
| EP-3335736-B1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARM INC (US) | 2020-12-30 | — | — | EP | disclosed |
| US-8487129-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8465725-B2 | Process for production of heterodimers of glutamic acid | Molecular Insight Pharmaceuticlas, Inc. (US) | 2013-06-18 | — | — | US | disclosed |
| US-20120269726-A1 | Heterodimers of Glutamic Acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2012-10-25 | — | — | US | disclosed |
| US-20120208988-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHTS PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20110008253-A1 | PROCESS FOR PRODUCTION OF HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2011-01-13 | — | — | US | disclosed |
| WO-2010147965-A2 | PROCESS FOR PRODUCTION OF HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| EP-2097111-A2 | HETERODIMERS OF GLUTAMIC ACID | Molecular Insight Pharmaceuticals, Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20080193381-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008058192-A2 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| EP-0444889-A1 | Novel synthesis of carbapenem intermediates | MERCK & CO. INC. (US) | 1991-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070695-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | CYP2A6 785/4885ALDH1A1 2259/4885TYR 2323/4885 |
| US-12534429-B2 | Heterodimers of glutamic acid | FOLH1, GLUL, SLC25A13 | CYP2A6 852/4885ALDH1A1 1911/4885TYR 2060/4885 |
| US-20110008253-A1 | PROCESS FOR PRODUCTION OF HETERODIMERS OF GLUTAMIC ACID | GLUL, GCLC, GLRA2 | CYP2A6 1500/4885ALDH1A1 1808/4885TYR 1829/4885 |
| US-20120269726-A1 | Heterodimers of Glutamic Acid | DDO, GLUL, ASNS | CYP2A6 807/4885ALDH1A1 2242/4885TYR 2344/4885 |
| US-20080193381-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | CYP2A6 785/4885ALDH1A1 2259/4885TYR 2323/4885 |
| US-20210070696-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | CYP2A6 784/4885ALDH1A1 2269/4885TYR 2331/4885 |
| US-20120208988-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | CYP2A6 785/4885ALDH1A1 2259/4885TYR 2323/4885 |
| US-20230095637-A1 | Heterodimers of Glutamic Acid | DDO, GLUL, ASNS | CYP2A6 704/4885ALDH1A1 2182/4885TYR 2378/4885 |
| US-20210246103-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | CYP2A6 785/4885ALDH1A1 2259/4885TYR 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.